Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
  • The following term was not found in PubMed: in Combination Trialists' Group[Corporate Author].

Results: 1 to 20 of 193

1.

Current concepts in breast cancer chemoprevention.

Chlebowski RT.

Pol Arch Med Wewn. 2014;124(4):191-9. Epub 2014 Mar 10.

PMID:
24618912
[PubMed - in process]
Free Article
2.

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, Muñoz C, Vega E, Calderón MJ, Sancho B, Cortes-Funes H.

Breast. 2014 Jun;23(3):201-8. doi: 10.1016/j.breast.2014.01.016. Epub 2014 Mar 1.

PMID:
24589524
[PubMed - in process]
Free Article
3.

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group.

Ann Oncol. 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.

PMID:
24347518
[PubMed - in process]
4.

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M.

Lancet Oncol. 2013 Oct;14(11):1067-76. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12.

PMID:
24035531
[PubMed - indexed for MEDLINE]
5.

Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?

Aapro M, van de Velde CJ, Markopoulos C, Bartlett JM, Putter H, Coleman RE.

Breast. 2013 Aug;22(4):488-94. doi: 10.1016/j.breast.2013.01.007. Epub 2013 Feb 27.

PMID:
23454040
[PubMed - indexed for MEDLINE]
6.

Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.

Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R, Mehta RG.

J Steroid Biochem Mol Biol. 2013 Jan;133:30-42. doi: 10.1016/j.jsbmb.2012.08.004. Epub 2012 Aug 23.

PMID:
22939887
[PubMed - indexed for MEDLINE]
7.

Combination anastrozole and fulvestrant in metastatic breast cancer.

Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN.

N Engl J Med. 2012 Aug 2;367(5):435-44. doi: 10.1056/NEJMoa1201622.

PMID:
22853014
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).

Riemsma R, Forbes CA, Amonkar MM, Lykopoulos K, Diaz JR, Kleijnen J, Rea DW.

Curr Med Res Opin. 2012 Aug;28(8):1263-79. doi: 10.1185/03007995.2012.707643. Epub 2012 Jul 16. Review.

PMID:
22738819
[PubMed - indexed for MEDLINE]
9.
10.

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.

Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M, Landberg G; TransATAC investigators.

Breast Cancer Res. 2012 Apr 4;14(2):R57.

PMID:
22475046
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. Erratum in: J Natl Cancer Inst. 2012 Nov 21;104(22):1772.

PMID:
22395643
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

17α-ethynyl-5α-androstane-3α, 17β-diol treatment of MNU-induced mammary cancer in rats.

Ahlem CN, Frincke JM, White SK, Reading CL, Trauger RJ, Lakshmanaswamy R.

Int J Breast Cancer. 2011;2011:618757. doi: 10.4061/2011/618757. Epub 2011 Feb 14.

PMID:
22332014
[PubMed]
Free PMC Article
13.

Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.

Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M.

J Clin Oncol. 2012 Mar 1;30(7):722-8. doi: 10.1200/JCO.2011.36.8993. Epub 2012 Jan 23.

PMID:
22271481
[PubMed - indexed for MEDLINE]
14.

Human steroid biosynthesis for the oncologist.

Auchus ML, Auchus RJ.

J Investig Med. 2012 Feb;60(2):495-503. doi: 10.231/JIM.0b013e3182408567. Review.

PMID:
22222232
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S, Wolmark N.

J Clin Oncol. 2011 Nov 20;29(33):4365-72. doi: 10.1200/JCO.2011.35.3714. Epub 2011 Oct 17.

PMID:
22010013
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.

Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2011 Dec 15;17(24):7828-34. doi: 10.1158/1078-0432.CCR-11-1846. Epub 2011 Oct 13.

PMID:
21998336
[PubMed - indexed for MEDLINE]
Free Article
17.

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF.

J Clin Oncol. 2011 Nov 10;29(32):4273-8. doi: 10.1200/JCO.2010.31.2835. Epub 2011 Oct 11.

PMID:
21990413
[PubMed - indexed for MEDLINE]
18.

Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.

Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J.

J Clin Oncol. 2011 Nov 10;29(32):4266-72. doi: 10.1200/JCO.2011.35.5545. Epub 2011 Oct 11.

PMID:
21990403
[PubMed - indexed for MEDLINE]
19.

Autophagy and endocrine resistance in breast cancer.

Cook KL, Shajahan AN, Clarke R.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1283-94. doi: 10.1586/era.11.111. Review.

PMID:
21916582
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.

Lee SA, Hwang SH, Ahn SG, Lee HM, Jeong J, Lee HD.

Breast Cancer Res Treat. 2011 Dec;130(3):863-70. doi: 10.1007/s10549-011-1728-3. Epub 2011 Aug 23.

PMID:
21861101
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk